OpenAI announced on its website that it had acquired Orchestra Bio on Tuesday. The price was not disclosed. Orchestra had reportedly raised around $20 million as of 2025 from backers including Andreessen Horowitz, Atria and 8VC.
Orchestra builds agents that handle operational work in drug discovery, such as tracking finances and resolving scheduling problems in clinical trials. OpenAI plans to add the team and technology to Rosalind, its AI model for life sciences research, and to Rosalind Workbench, a tool meant to help researchers plan experiments and analyze results.
OpenAI says Moderna and Novo Nordisk are among its Rosalind customers. The deal fits a broader pattern in which large AI labs, including OpenAI and Anthropic, build more software for major industries such as pharma.
Why it matters if you build agents
Teams building agents for life sciences may see Rosalind gain operational agent features, such as finance tracking and trial scheduling, inside OpenAI's own product. Developers who rely on Orchestra's agents should watch for changes to access, pricing or support, which the announcement does not address. The deal is also a sign that vertical agent startups can be acquired by model labs rather than competed away by them.
Get stories like this every weekday
One short email with the day's agent tooling news.